Finding your next opportunity shouldn’t require piecing together multiple databases, alerts and research tools.
Fundz combines its own funding and M&A intelligence with hiring, leadership and other business signals into one connected view of each company, ranks opportunities against your ideal customer profile, and delivers the evidence and verified contacts to act on. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
C4 THERAPEUTICS, INC.
The company shared information publicly (Regulation FD). An 8-K is the notice a US public company must file within four business days of a major event.
C4 TherapeuticsAI Executive Summary
AI-powered analysis of 8-K filing content
C4 Therapeutics announced new biomarker data from Phase 1 trials of Cemsidomide with Dexamethasone and Phase 1b trials of Elranatamab (ELREXFIO®) for relapsed/refractory Multiple Myeloma at the 23rd International Myeloma Society Annual Meeting, signaling clinical progress that could strengthen the company's pipeline and investor confidence.
Key Takeaways
C4 Therapeutics presented new biomarker data from Cemsidomide Phase 1 trial in combination with Dexamethasone for Multiple Myeloma treatment
Phase 1b trial data for Elranatamab (ELREXFIO®) was shared, demonstrating advancements in relapsed/refractory Multiple Myeloma treatment
2 more takeaways
Filing Overview
What This Means
C4 THERAPEUTICS, INC. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.